SEQUENCE LISTING

```
<110> De Strooper, Bart
      Annaert, Wim
<120> Binding Domains Between Presentlins and Their Substrates
      as Targets for Drug Screening
<130> 2676-6086US
<150> PCT/EP/02/043033
<151> 2002-03-15
<150> EP01201015.3
<151> 2001-03-16
<160> 22
<170> PatentIn version 3.2
<210> 1
<211> 21
<212> PRT
<213> Artificial
<220>
<223> Human transmembrane region 1 of presentlin 1
<400> 1
Val Ile Met Leu Phe Val Pro Val Thr Leu Cys Met Val Val Val Val
                                   10
Ala Thr Ile Lys Ser
           20
<210>
      2
<211> 21
<212> PRT
<213> Artificial
<220>
<223> Human transmembrane region 1 of presentlin 2
```

```
<400> 2
Val Ile Met Leu Phe Val Pro Val Thr Leu Cys Met Ile Val Val Val
                                   10
Ala Thr Ile Lys Ser
            20
<210>
<211> 8
<212> PRT
<213> Artificial
<220>
<223> carboxy-terminal of human presentlin 1
<400> 3
Leu Ala Phe His Gln Phe Tyr Ile
1
                5
<210> 4
<211> 8
<212> PRT
<213> Artificial
<220>
<223> carboxy-terminal of human presentlin 2
<400> 4
Leu Ala Ser His Gln Leu Tyr Ile
                5
<210> 5
<211> 11
<212> PRT
<213> Artificial
<220>
<223> Part of the transmembrane region of human APP
```

```
<400> 5
Thr Val Ile Val Ile Thr Leu Val Met Leu Lys
<210> 6
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Part of the transmembrane region of telencephalin
<400>
     6
Val Ala Gly Pro Trp
                5
<210> 7
<211> 34
<212> PRT
<213> Artificial
<220>
<223>
       synthesized peptide
<220>
<221> SITE
<222> (19)..(34)
<223>
      conserved transmembrane region
<400>
      7
Val Val Ile Ala Thr Val Ile Val Ile Thr Leu Val Met Leu Lys Lys
                                    10
Lys Gln Cys Arg Gln Leu Arg Ile Ala Gly Arg Arg Leu Arg Gly Arg
                                25
```

Ser Arg

```
<210> 8
<211> 18
<212> PRT
<213> Artificial
<220>
<223> synthesized peptide
<400> 8
Val Val Ile Ala Thr Val Ile Val Ile Thr Leu Val Met Leu Lys Lys
                                    10
Lys Gln
<210> 9
<211> 17
<212> PRT
<213> Artificial
<220>
<223>
      synthesized peptide
<220>
<221> misc_feature
<222> (1)..(1)
<223> X is a palmityol group
<400> 9
Xaa Leu Val Gln Pro Phe Met Asp Gln Leu Ala Phe His Gln Phe Tyr
                                    10
                                                        15
Ile
<210> 10
<211> 32
<212> PRT
<213> Artificial
```

```
<220>
<223> synthesized peptide
<220>
<221> SITE
<222> (1)..(16)
<223> conserved transmembrane region
<400> 10
Gly Arg Gln Leu Arg Ile Ala Gly Arg Arg Leu Arg Gly Arg Ser Arg
Leu Val Gln Pro Phe Met Asp Gln Leu Ala Phe His Gln Phe Tyr Ile
                                25
<210> 11
<211> 16
<212> PRT
<213> Artificial
<220>
<223> synthesized peptide
<400>
     11
Leu Val Gln Pro Phe Met Asp Gln Leu Ala Phe His Gln Phe Tyr Ile
                                    10
                                                        15
1
                5
<210> 12
<211> 31
<212> PRT
<213> Artificial
<220>
<223> synthesized peptide
<220>
<221> SITE
<222>
      (16)..(31)
<223> conserved transmembrane region
```

```
<400> 12
Ala Thr Val Ile Val Ile Thr Leu Val Met Leu Lys Lys Gln Gly
Arg Gly Leu Arg Ile Ala Gly Arg Arg Leu Arg Gly Arg Ser Arg
                               25
<210> 13
<211> 15
<212> PRT
<213> Artificial
<220>
<223>
      synthesized peptide
<400> 13
Ala Thr Val Ile Val Ile Thr Leu Val Met Leu Lys Lys Gln
               5
                                                       15
1
                                   10
<210> 14
<211>
      9
<212> PRT
<213> Artificial
<220>
<223> synthesized peptide
<220>
<221>
      misc_feature
<222>
      (1)..(1)
<223>
      X is a palmityol group
<400>
     14
Xaa Leu Ala Phe His Gln Phe Tyr Ile
               5
1
```

<210>

<211> 13

15

```
<212> PRT
<213> Artificial
<220>
<223> synthesized peptide
<220>
<221> misc_feature
<222>
      (1)..(1)
<223> X is a palmityol group
<400> 15
Xaa Phe Met Asp Gln Leu Ala Phe His Gln Phe Tyr Ile
                                    10
<210> 16
<211> 24
<212> PRT
<213> Artificial
<220>
<223> synthesized peptide
<220>
<221> SITE
<222> (1)..(16)
<223> conserved transmembrane region
<400> 16
Gly Arg Gln Leu Arg Ile Ala Gly Arg Arg Leu Arg Gly Arg Ser Arg
                                    10
                                                       15
Leu Ala Phe His Gln Phe Tyr Ile
           20
<210> 17
<211> 28
<212> PRT
<213> Artificial
<220>
```

```
<223> synthesized peptide
<220>
      SITE
<221>
      (1)..(16)
<222>
       conserved transmembrane region
<223>
<400> 17
Gly Arg Gln Leu Arg Ile Ala Gly Arg Arg Leu Arg Gly Arg Ser Arg
                                                        15
                                    10
                5
Phe Met Asp Gln Leu Ala Phe His Gln Phe Tyr Ile
                                25
            20
<210> 18
<211> 8
<212> PRT
<213> Artificial
<220>
       synthesized peptide
<223>
<400>
      18
Leu Ala Phe His Gln Phe Tyr Ile
                 5
1
<210> 19
 <211> 12
<212> PRT
 <213> Artificial
 <220>
<223> synthesized peptide
 <400> 19
 Phe Met Asp Gln Leu Ala Phe His Gln Phe Tyr Ile
                                     10
```

```
<210> 20
<211> 16
<212> PRT
<213> Artificial
<220>
<223> synthesized peptide
<220>
<221> SITE
<222>
      (1)..(16)
<223> conserved transmembrane region
<400> 20
Gly Arg Gln Leu Arg Ile Ala Gly Arg Arg Leu Arg Gly Arg Ser Arg
                                                        15
                                    10
<210> 21
<211> 18
<212> PRT
<213> Artificial
<220>
<223> synthesized peptide
<220>
<221> MISC_FEATURE
<222> (1)..(18)
      c-terminal amino acids of mouse TLN coupled to KLN
<223>
<400> 21
Gly Ala Glu Gly Gly Ala Glu Thr Pro Gly Thr Ala Glu Ser Pro Ala
                                                        15
                                    10
Asp Gly
<210> 22
<211>
       15
<212> PRT
```

<213> Artificial

<220>

<223> synthesized peptide

<400> 22

Met Ala Asp Ile Lys Asn Asn Pro Glu Tyr Ser Ser Lys Leu His 1 5 10 15